• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT

    8/26/24 9:15:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted business TV show, announces episode 591, airing on the Fox Business Network tonight, Monday, August 26, 2024, at 10:30 PM PT.

    New to The Street's 591st TV episode line-up features the following five (5) Corporate interviews:

    1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO.

    2). "Game Changers" segment interview with Iagon's (CRYPTO: IAG) ($IAG) Dr. Navjit Dhaliwal, CEO.

    3). "Game Changers" segment interview with GreenLite Ventures, Inc.'s (OTC:GRNL) ($GRNL) (No Limit Technology Holdings, Inc.) Rafael Groswirt, CEO

    4). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTC:SGTM) ($SGTM) Tony Raynor, CEO and Founder.

    5). "Sekur Privacy & Sekur Security – The Weekly Hack" segment with internet privacy expert Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) ($SWISF) (Sekur®).

    Episode 591

    From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ($ACXP) ("Company"), a late-stage biopharmaceutical Company that publicly trades on the NASDAQ market. ACXP is developing a new class of small molecular antibiotics for the most common life-threatening bacterial infections. Recently, the Company completed its FDA Phase 2 clinical trials on its Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Management is now meeting with the FDA regarding the steps necessary to complete the Phase 3 clinical trial on the drug. Concurrently, ACXP is meeting with the FDA on the drug manufacturing processes, which must meet the government's standards. Management remains confident that Ibezapolstat can be manufactured and inventoried before the conclusion of 2024. The United States Patent and Trademark Office (USPTO) has issued a patent because the drug can, in treated patients, maintain and restore microbiome bacteria. Most pharmaceuticals destroy the gut's microbiome bacteria, which is the major cause of diseases and reinfections, typically caused by competitor drugs for CDI. The issued patent remains valid until June 2042. The Company is working globally with several entities seeking partnerships and other collaborations on non-dilutive financing arrangements for the funding needs of the FDA Phase 3. The objective is to get funded without using ACXP's stock, which will not dilute shareholders' value. David started a program to work with college students, being a mentor to assist students in bringing their scientific ideas to market. With the FDA and USPTO continuing to provide timely approvals, the Company has shown that its Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.

    New to The Street airs its "Game Changers" segment with TV Host and Multi-media Journalist Ana Berry, who talks with Dr. Navjit Dhaliwal ("Nav"), CEO of Iagon (CRYPTO: IAG) ($IAG). As a decentralized cloud storage platform that leverages blockchain technology, Iagon is disrupting the data storage industry. As "Game Changers," Iagon redefines the concept of data storage and transmission, providing individuals and organizations with security and transparency. The typical data storage business model has information on a single server at a location. Many Big Tech platforms providing this centralized service have had many server cybersecurity breaches, with data stolen. The Iagon approach is uniquely different; it is a decentralized platform with enhanced security features offered through the blockchain. Because the decentralization of data allows for information to be stored globally on many different nodes and servers, data is more secure, diminishing the chances of data hacking. Iagon's platform fully complies with the needs of many industries and agencies, which require secure and transparent data platforms under governmental rules, regulations, and laws. All end-users have complete control of stored data files. Another benefit is cost savings. Since Iagon does not need expensive infrastructure and servers, it can offer services at a fraction of the cost compared to centralized systems. Iagon allows individuals and organizations to bring their storage capacities onto a decentralized AI platform and receive IAG coins as a reward. The Company has two new product offerings, the "Cyclone" and "May Net Compute," which provide individuals and organizations easy access to a decentralized data storage and transmission platform while offering security and transparency. As "Game Changers," Iagon's AI blockchain decentralized data storage ecosystem continues to grow, giving onboard end-users complete data control with advanced data storage and security methods. The on-screen QR code is available during the show; download or visit Iagon - https://iagon.com/.

    New to The Street's "Game Changers" segment interview is with Rafael Groswirt, CEO of GreenLite Ventures, Inc. (OTC:GRNL) ($GRNL) ("Company"). TV Host Ana Berry talks with Rafel talk about the Company's "Game Changers" in the digital sports and finance industries. Recently, the GRNL completed the merger and acquisition of No Limit Technology Holdings, Inc. ("No Limit'), a business in the sports betting and cryptocurrency markets. Rafael explains the process and the eventual success of the merger and gives an overview of the value proposition of being a public entity. Management is looking to advance its capabilities in the digital sports betting arena with a decentralized ecosystem. Rafael believes GRNL has a huge competitive advantage over its competitors through blockchain technology, cryptocurrency, AI, and other technologies. With new business developments with multiple digital platforms while looking to launch media channels, No Limit believes it can revolutionize and disrupt the industry while giving end-users a new and unique fantasy sports betting experience that is otherwise unavailable on competitors' platforms. GRNL's digital sports and financial platform are "Game Changers." The on-screen QR code is available during the show; download or visit No Limit Technology Holdings, Inc. - https://www.nolimitfantasysports.com/.

    The Sustainable Green Team, Ltd.'s (OTCQX:SGTM) ($SGTM) ("Company")Tony Raynor, CEO and Founder, is with New to The Street's TV Host Jane King. Talking about the Company from the Nasdaq MarketSite Studio, viewers get an insight into SGTM's environmentally sustainable solutions. Tony informs viewers about the Company's partnership with Jimmy Houston, founder of Jimmy Houston Outdoors, a TV Host, and a Social Media influencer, who has an extensive media and online network and is known for product and service endorsements. With millions of followers and a highly rated show on ESPN, Jimmy always promotes a sustainable agenda to protect fish and wildlife. SGTM and Jimmy will work together to promote SGTM's sustainable product lines and offer a platform for SGTM to launch new goods and services. SGTM creates, produces, and sells sustainable, chemical-free products by converting waste into high-value, nutrient-rich products. New products forthcoming will focus on the health and well-being of livestock and wildlife. Jimmy offers SGTM a platform to endorse current and future products. Tony informs viewers that the Company is producing a media program that will air on Bloomberg TV as a "Bloomberg Original" series. The show will focus on global problems, educating many on how sustainable solutions can restore and replenish the Earth. Influential leaders and businesspeople will be on the show, highlighting current global environmental concerns and the solutions available to make people, plants, and animals healthier; a healthy planet makes for healthy inhabitants. SGTM is soon rolling out new product lines, becoming available at "Big Box" retailers. The Company has a YouTube channel with many informative videos about the Company and its sustainable initiatives and products. The on-screen QR code is available during the shows: The Sustainable Green Team, Ltd. - https://www.thesustainablegreenteam.com/.

    New to The Street airs its "Sekur Privacy & Sekur Security – The Weekly Hack" segment. Alain Ghiai, an internationally acclaimed internet privacy expert and the CEO of Sekur Private Data, Ltd.  (OTCQX:SWISF) (CSE:SKUR) (FRA: GDT0) ($SWISF) (Sekur®) talks with TV Host and Multi-media Journalist Ana Berry about another hack at AT&T. It appears that hackers stole at least six months of its customers' calls and text message records. AT&T used a 3rd party cloud base database to store these records, which became compromised. Unfortunately, five to seven of the largest technology companies control the world's data storage and transmissions. One of those is CrowdStrike, which recently had a significant outage, shutting down thousands of its customers' access to programs and data. CrowdStrike program failure completely shut down Delta Airlines, frustrating passengers and employees. Sekur is different, providing close-loop access with military encrypted programs on the Company's own and controlled servers in Switzerland. Individuals, businesses, and governmental agencies can all benefit from subscribing to Sekur. To avoid cyberhackers' attempts, subscribers send information through the Company's SekurVPN, SekurMail, and SekurMessenger services, giving end-users private and secure electronic communications. SekurMail, with SekurSend/SekurReply options, sends a link to a recipient to open an email in the closed loop encrypted military platform. The service protects both the subscriber and the recipient, even if the recipient is not a Sekur subscriber. SekurMessenger offers many secure options that prevent text messages from appearing on open BIG Tech platforms. Using SekurMail with the Company's SekurVPN adds another layer of encryption that protects its subscribers' IP addresses and website traffic information. Any entity under regulatory scrutiny can comply with Sekur services. The services are available through iOS and Android apps, and those not interested in downloading apps can use the Company's web-based platforms. Alan states that being more invisible on the net and shrinking your cybersecurity footprint should most likely lessen the chances of becoming a hacked victim. Under Swiss law, your IP address is private property protected by stringent regulations. The Company never tracks your devices, never sells data, doesn't use 3rd party platforms, never asks for phone numbers, and keeps one's internet traffic private and secure. PROMO CODE: PRIVACY is now available, giving 15% savings toward monthly and yearly subscriptions, and the discount will remain active for five years. Viewers, please tune in next time for the newest cybersecurity topic on the "Sekur Privacy & Sekur Security– Weekly Hack" segment. The on-screen QR code is available during the shows to download more info or visit Sekur Private Data, Ltd. – https://sekurprivatedata.com/, http:/sekur.com/ and https://sekur.com/en/vpn. Privacy has arrived!

    About Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ($ACXP):

    Acurx Pharmaceuticals, Inc.(NASDAQ:ACXP) ($ACXP) is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP) - https://www.acurxpharma.com/.

    About Iagon (CRYPTO: IAG) ($IAG):

    Iagon (CRYPTO: IAG) ($IAG) was founded in 2017 in Hamar, Norway, because people need to control their data. The idea started as an attempt to solve significant issues related to how healthcare data is stored, with modern solutions severely lacking transparency for individuals at a national and international level. The protocol will allow storage providers to earn rewards by trading their excess storage to resource consumers on a marketplace at a transparent price while ensuring data privacy, security, and accessibility. Its token-based economy is based on computer, server, and data center owners who join the storage and processing power grids. In return for sharing the capabilities of their machine, they will be granted Iagon tokens that can be traded back to fiat money, while any party who wishes to utilize their capabilities will purchase tokens to distribute to the parties that provide their services to the blockchain grid - https://iagon.com/.

    About GreenLite Ventures, Inc. (OTC:GRNL) ($GRNL)/ No Limit Technology Holdings, Inc.:

    Greenlite Ventures, Inc. (OTC:GRNL) ($GRNL) acquired No Limit Technology Holdings, Inc., a fantasy sports betting platform. With the use of AI and cryptocurrency, the Company's NoLimitCoin (CRYPTO: NLC2) offers a unique payment platform for end-users on its online gaming application. End-users making wagers on No Limit's fantasy sports platform bet on the best possible outcome on players' performances. Winners who make successful wagers are rewarded based on performances - https://www.nolimitfantasysports.com

    About Sustainable Green Team, Ltd. (OTC:SGTM) ($SGTM):

    Sustainable Green Team, Ltd. (OTC:SGTM) ($SGTM) is a leading Company in climate reversing technologies, a provider of sustainable solutions to improve environmental health, promote sustainable practices, and deliver eco-friendly products and services. SGTM aims to make significant contributions to global sustainability; learn more by visiting the Company website, https://thesustainablegreenteam.com/, SGTM's YouTube Channel, Corporate Bloomberg TV commercial - https://www.youtube.com/watch?v=d_0rLESvJJ0, corporate video - https://www.youtube.com/watch?v=xJ7Dp9Coi88&t=1s and SGTM's Blogs - https://thesustainablegreenteam.com/sgtm-blog.

    About Sekur Private Data Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) ($SWISF):

    Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) ($SWISF) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted emails, and secure communication tools. It sells its products through its websites, www.sekur.com, approved distributors, and telecommunication companies worldwide. Sekur Private Data, Ltd. serves consumers, businesses, and governments worldwide - https:/sekurprivatedata.com and  https://sekur.com; Twitter: @sekurprivate.

    About New to The Street:

    New to The Street is an FMW Media production that operates one of the longest-running US and International sponsored and syndicated Nielsen-rated programming television brands, "New to The Street." Since 2009, New to The Street has run biographical interview segment shows across major U.S. television networks. The Nielsen-rated and sponsored broadcast programming platform reaches millions of homes in the US and international markets. FMW's New to The Street show appears on Bloomberg and the FOX Business Network as sponsored programming. FMW is also one of the nation's largest buyers of linear television, long and short-form paid programming - https://newtothestreet.com/.

    Forward-Looking Statements Disclaimer US/Canada:

    This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements do not guarantee future performance or results and will not necessarily be accurate indications of when such performance or results are achieved. This press release should be considered in all companies' filings contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

    This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as "seek," "anticipate," "believe," "plan," "estimate," "expect," "likely," and "intend" and statements that an event or result "may," "will," "should," "could" or "might" occur or be achieved and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting, the foregoing expectations. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    CONTACT:

    New to The Street

    Monica Brennan

    [email protected]

    https://newtothestreet.com/

    1-917-330-2564

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6bb75ce3-639a-4971-9114-4a2c3a0d2893



    Primary Logo

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    $2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced

    4/16/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

    STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, alo

    3/30/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:47:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Luci David P

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:46:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Deluccia Robert J

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:45:47 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    11/29/21 8:33:36 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    SEC Filings

    View All

    Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    4/16/26 8:14:23 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Acurx Pharmaceuticals Inc.

    424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    4/16/26 8:13:38 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Acurx Pharmaceuticals Inc.

    S-8 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/12/26 4:15:31 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.   Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: On August 4, 2025, we effected a 1-for-20 reverse stock split of our issued and outstanding shares of common stock, and as a result of the reverse-stock-split, on August 26, 2025, we regained compliance with the minimum bid price requirement of

    11/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/24 2:39:21 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:59:03 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:52:45 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care